Drug-eluting stents (DES) in percutaneous coronary interventions significantly reduce rates of restenosis and the need for new revascularizations compared with bare metal stents. However, as the use of DES has increased dramatically, questions have been raised about their long-term safety. Concerns about an increased risk of late stent thrombosis, particularly beyond the first year of treatment, have arisen and have been exacerbated by sparse and conflicting information, and boosted an intense debate between cardiologists. In this article, we reviewed the most recent information to clarify the conundrum of late stent thrombosis and the long-term safety of DES.
Introduction
Coronary stents are used in more than 90 percent of percutaneous coronary interventions (PCI), owing to their effect on reducing early complications and late restenosis as compared to conventional balloon angioplasty [Fischman et al. 1994; Serruys et al. 1994 ]. However, in-stent restenosis still occurs in 10 to 50% of the patients, depending upon a number of clinical, angiographic, and procedural variables Serruys et al. 1999; Mercado et al. 2001 ].
Drug-eluting stents (DES), by combining the advantages of a stent scaffold with controlled release of an antiproliferative agent to prevent restenosis, have reduced the need of such procedures by 50 to 70% [Moussa et al. 2004; Stone et al. 2004] , and significantly changed the practice of interventional cardiology. Recently, however, several studies reported an increased risk of stent thrombosis (ST) in patients with DES after 1 year [Wessely et al. 2005; Joner et al. 2006; Pfisterer et al. 2006 ]. This evoked considerable concern from the cardiologists, the health care providers, the regulatory bodies, the media, and the patients, because of the recognized association between ST and serious adverse clinical events, such as myocardial infarction and death.
The aim of this article is to review the possible mechanisms of late stent thrombosis following DES implantation and to summarize the available data on DES safety over long-term follow-up.
Physiopathology of drug-eluting stent thrombosis
Stent thrombosis may occur acutely (within 24 hours of stent placement), subacutely (up to 30 days after stent implantation), as late thrombosis (after 30 days), or as very late thrombosis (after 12 months). Several factors may contribute to ST, including procedurerelated factors, patient-and lesion-related factors, antiplatelet therapy, thrombogenicity of the stent [Luscher et al. 2007 ]. Procedural risk factors for acute and subacute stent thrombosis are stent length, placement of multiple stents, stent underexpansion and residual reference segment stenosis, bifurcation, slow coronary blood flow, positive remodeling, residual dissections. All those factors are very unlikely to differ between DES and bare metal stents (BMS). Clinical conditions linked to increased probability of acute and subacute ST are acute myocardial infarction, diabetes mellitus, renal failure, and low ejection fraction, and this holds true for both DES and BMS. Indeed, all major clinical trials and observational registries showed no differences in the incidence of acute and subacute ST between DES and BMS.
Differently, DES presents some specific characteristics that may favour late and very late stent thrombosis, especially after withdrawal of double antiplatelet therapy [McFadden et al. 2004 ], a phenomenon extremely rare with BMS. Both the first generation DES, the Cypher TM sirolimus-eluting stent (Cordis, Johnson & Johnson, Miami Lake, FL, USA) and the TAXUS TM paclitaxel-eluting stent (Boston Scientific, Natick, MA, USA), as well as most of the new DES systems, release biological agents locally through a polymer carrier. The polymer carriers may have different biocompatibility and can elicit inflammation and hypersensitivity reactions, predisposing to late thrombosis [Virmani et al. 2004] . Certainly, however, the most important drawback of DES is delayed endothelial healing (i.e., the failure to form a complete neointimal layer over stent struts), which is a side-effect strictly linked to their mechanism of action. Smooth muscle cell proliferation is the main target in the effort to prevent or reduce in-stent restenosis. The biological agent carried by the stent should interfere with one or more steps involved in this process, and this is obtained through the inhibition of cell cycle progression at different stages. Sirolimus inhibits cellular proliferation by blocking cell cycle progression at the G1 to S transition [Marx and Marks, 2001] , whereas paclitaxel enhances the assembly of very stable microtubules, interrupting proliferation, migration and signal transduction [Sollott et al. 1995] . Unfortunately, these effects are not specific for smooth muscle cells, and they affect also endothelial cell proliferation. Indeed, in autopsy [Joner et al. 2006] and angioscopy [Kotani et al. 2006 ] series both sirolimus-(SES) and paclitaxel-eluting stents (PES) showed greater delayed healing characterized by persistent fibrin deposition and poorer endothelialization compared with BMS, regardless of time point. BMS appeared completely covered by 6 to 7 months after implantation, whereas even beyond 40 months DES are not fully endothelialized [Joner et al. 2006 ].
Incomplete apposition of the stent to the vessel wall due to suboptimal expansion is a recognized risk factor for acute and subacute ST for both DES and BMS. Malapposition of the stent to the vessel wall might also develop months after the PCI ('late acquired malapposition'), and this phenomenon has been described more frequently in DES patients than in the control arms as a result of impaired vascular healing [Serruys et al. 2002] . However, the clinical significance of acquired malapposition is controversial and not clearly linked to ST.
Hence, the cause of DES late thrombosis is likely multifactorial with some clinical and procedural risk factors predisposing also to late BMS thrombosis [Farb et al. 2003; Daemen et al. 2007] , and other more specific to DES. Impaired intimal healing extends the window during which DES are prone to thrombosis. Antiplatelet withdrawal over long term followup is therefore more dangerous in DES-treated patient. Unfortunately, at the moment we have no means of predicting endothelial recovery and to recommend safely the interruption of dual antiplatelet therapy.
Do drug-eluting stent increase mortality? The September 2006 'Firestorm'
Two separate meta-analysis that summarized published studies on SES and PES trials were presented at the World Congress of Cardiology meeting in Barcelona, in September 2006 [Nordmann et al. 2006 Carmenzind et al. 2007] , showing increased mortality associated to DES. These studies compiled data in the published literature, and the authors did not have access to the primary patient information or to updated information from follow-up that was ongoing. Despite these important limitations they had a major impact on clinical practice, causing a sharp reduction of DES utilization, and raised a heated debate in the scientific community that had profoundly echoed on the media. Fears of serious adverse clinical events ascribable to DES use over long-term follow-up were reinforced by other studies, especially the Basel Stent Cost Effectiveness Trial (BASKET) [Brunner-La Rocca et al. 2007] , and the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) [Lagerqvist et al. 2007 ]. In the latter, DES were associated with an increased rate of death after 6 months, and a composite of death or myocardial infarction was 0.5 to 1.0 percentage point higher per year as compared to BMS.
For these reasons, the US Food and Drug Administration (FDA) convened an urgent meeting of the Circulatory System Medical Devices Advisory Panel in December 2006, in order to collect all available information and to issue unbinding recommendations for clinical use of DES and for planification of future studies [Laskey et al. 2007 ]. Panelists recognized a number of caveats in the assessment of DES safety.
(1) ST definition varies from study to study and this make it difficult to ascertain the true incidence, and it might be not correct to pool studies together and to compare one stent to another.
(2) ST occurring subsequent to any targetlesion revascularization were excluded from the counts of episodes of ST in most of the trials because of censoring. Because BMS patients Review are more likely to need a new revascularization, more BMS patients were censored and this may have introduced a bias against DES with regard to the on-protocol definitions of ST.
(3) The number of patients enrolled in clinical trials is probably too low to detect a significant difference in the incidence of events as infrequent as ST and its clinical consequences.
(4) Metaanalyses performed as patient-level analyses should be preferred to group-level analysis because of the ability to use appropriate statistical techniques to compare groupings with the individual patient data, to include patients who may have been excluded from the publications, and to perform adjustment for potential confounders of the comparisons. However, both types of analysis are limited by heterogeneity in the studies that may not be amenable to post-hoc adjustments.
A new standardized definition of ST for uniform evaluation of events in different trials had been developed by the Academic Research Consortium (ARC) ], composed of representatives of international academic research organizations who were involved in designing these trials, representatives of the FDA, and representatives of manufacturers of DES (Table 1 ). The FDA considered that the ARC definitions were acceptable and requested that sponsors and investigators apply these definitions to their data sets when possible.
Safety of 'On-Label' DES use
'On-label' indications are typically defined by the inclusion and exclusion criteria of the pivotal clinical trials submitted to support device approval. Accordingly, the FDA labeled indication for the SES is the treatment of discrete de novo lesions of length ≤30 mm in native coronary arteries with reference vessel diameter of >2.5 mm to <3.5 mm, and for the PES is the treatment of de novo lesions ≤28 mm in length in native coronary arteries ≥2.5 to ≤3.75 mm in diameter. Long-term safety of DES for 'on-label' indications therefore coincides with the results of randomized clinical trials.
The 4-year clinical outcome of DES patients was assessed in a pooled patient-level analysis analysis of data from four double-blind clinical trials comparing SES and BMS, and five trials comparing PES and BMS (Figures 1 and 2) [Stone et al. 2007 ]. Rates of per-protocol defined stent thrombosis were 1.2% in the SES group versus 0.6% in the BMS group (P = 0.20) and 1.3% in the PES versus 0.9% in the BMS group (P = 0.30). No significant differences were detected also by the ARC ST definition (with categories of definite and probable) (SES 1.5% versus BMS 1.8%, P = NS; PES 1.9% versus BMS 1.5%, P = NS) [Laskey et al. 2007 ]. For both stents, after 1 year there were significantly more episodes of ST in comparison to BMS. However, the 4-year cumulative frequency of death, MI, or the combination Table 1 . Academic Research Consortium definitions of stent thrombosis ].
Event Definition
Definite Angiographic confirmation: • TIMI 0 with occlusion originating in or within 5 mm of stent in the presence of a thrombus or • TIMI flow grade 1, 2, or 3 originating in or within 5 mm of stent in the presence of a thrombus AND ≥1 of the following criteria <48 hours:
• New acute onset of ischemic symptoms at rest (typical chest pain with duration >20 minutes) • New ischemic ECG changes suggestive of acute ischemia • Typical rise and fall in cardiac biomarkers Pathologic confirmation:
• Evidence of recent thrombus within the stent determined at autopsy or via examination of tissue retrieved following thrombectomy of death and MI was not significantly different in patients treated with either the SES or PES stents compared with those treated with BMS. The expanded 5-year follow-up of these trials has been recently reported, and substantially confirmed these results (personal communication, TCT 2007, Washington DC).
Thus, for on-label use the data are consistent with a numerical increase in very late ST associated with DES use compared with BMS, but that the true magnitude of the risk and the duration of the risk are uncertain.This risk does not seem to translate into increased rates of mortality and MI. Therefore, when used in accordance with their labeled indications, both the SES and the PES can be considered safe and effective.
Results of large metanalyses and registries
Results of a meta-analysis of 38 trials (18,023 patients) with a follow-up of up to 4 years comparing SES and PES to BMS showed no significant differences for all-cause mortality and cardiac mortality between the three groups [Settler et al. 2007 ]. DES reduced the need for repeat revascularization by between 50% and 70%. The SES were associated with the lowest risk of myocardial infarction (HR 0.81, 95% credibility interval 0.66-0.97, p = 0.030 vs BMS; 0.83, 0.71-1.00, p = 0.045 vs PES). There were no significant differences in the risk of definite ST during the entire follow-up. However, the risk of late definite ST (>30 days) was increased with PES (HR 2.11, 95% credibility interval 1.19-4.23, p = 0.017 vs BMS; 1.85, 1.02-3.85, p = 0.041 vs SES).
Another metanalysis of individual data on 4,958 patients enrolled in 14 randomized trials comparing SES with BMS (mean follow-up interval, 12.1 to 58.9 months) was reported by Kastrati and colleagues ]. The overall risk of death (hazard ratio [HR], 1.03; 95% confidence interval [CI], 0.80 to 1.30) and the combined risk of death or myocardial infarction (HR, 0.97; 95% CI, 0.81 to 1.16) were not significantly different for patients receiving SES versus BMS up to 5 years. Even if no significant difference was detectable in the overall risk of ST with SES (HR, 1.09; 95% CI, 0.64 to 1.86), there was evidence of a slight increase in the risk of stent thrombosis associated with SES after the first year (0.6% SES vs 0.05% BMS, P = 0.02).
The clinical outcome of DES utilization has been assessed also in several 'real-world' registries [Daemen et al. 2007; Jensen et al. 2007; Marzocchi et al. 2007; Tu et al. 2007 or death and myocardial infarction (relative risk 1.01, 95% CI 0.94-1.09). In prespecified landmark analyses using a cutoff point at six months, investigators found a bimodal distribution of risk, with a trend toward reduced death in DEStreated patients and significant reductions in MI and death/MI, followed by a trend toward increased death and significantly higher rates of death/MI and MI alone after six months.
We recently reported the 2-year results of the large multicenter REAL registry, that prospectively enrolled 10,629 patients undergoing elective PCI with either DES (n = 3,064) or BMS (n = 7,565) [Marzocchi et al. 2007] . A large proportion of the patients were treated in 'offlabel' settings. The propensity-score adjusted 2-year cumulative incidence of death was 6.8% in the DES group and 7.4% in the BMS group (P = 0.35), and rates of myocardial infarction were 5.3% in DES and 5.8% in BMS (P = 0.46). Angiographic stent thrombosis was 1.0% in the DES group and 0.6% in the BMS group (P = 0.09). A further analysis of ST according to ARC definitions was performed on a matched population of 3,354 patients (n = 1677 for each treatment group), showing similar incidence for BMS and DES. The 3-year follow-up confirmed these results, showing an overall higher incidence of very late ST in the DES group without a negative impact on death and MI rates.
Data from the Cardiac Care Network of Ontario's population-based clinical registry were used to identify a well-balanced cohort of 3,751 pairs of patients, matched on the basis of propensity score, who received either BMS alone or DES alone [Tu et al. 2007 ]. After 2 years, DES were associated with significantly lower revascularizations, though the efficacy was limited to patients at higher risk of restenosis. The 3-year mortality rate was significantly higher in the BMS group than in the DES group (7.8% vs. 5.5%, P < 0.001), whereas the 2-year rate of myocardial infarction was similar in the two groups (5.2% and 5.7%, respectively; P = 0.95).
The Western Denmark Heart Registry enrolled 12,395 consecutive patients (DES n = 3,548 and BMS n = 8,847) followed for 15 months [Jensen et al. 2007 Data from the large two-institutional (Bern-Rotterdam) cohort study were analysed to ascertain the incidence, time course, and correlates of ST [Daemen et al. 2007 ]. Overall, 8,146 patients were evaluated (SES n = 3,823; PES n = 4,323). Angiographically documented stent thrombosis occurred in 152 patients (incidence density 1.3 per 100 person-years; cumulative incidence at 3 years 2.9%). Most of the episodes of ST (60%) occurred within the first month after the procedure, with similar incidence between SES and PES. However, late ST occurred steadily at a constant rate of 0.6% per year up to 3 years after stent implantation, and it was more frequent with PES (1.8%) than with SES (1.4%; p = 0.031). Interestingly, at the time of stent thrombosis dual antiplatelet therapy was being taken by 87% (early) and 23% (late) of patients.
Safety of 'Off-label' DES use
It is estimated that as much as 60% of DES use may be off-label and occurs in more complex patients and with more complex coronary artery lesions (Table 2) . Data from the 'real-world' stent registries confirmed a persistent and consistent reduction in the need for new revascularizations associated to DES utilization also in these settings [Laskey et al. 2007] . As expected, the rate of serious adverse events associated with DES appeared higher in these off-label populations as compared with their on-label counterparts. However, this
Review figure likely reflects the increased complexity of the patients and the lesions and the safety profile of DES in these scenarious does not seem to deviate dramatically from that of BMS. Available data are inadequate to draw definitive conclusions but some authors suggest that the benefit/risk ratio of DES could be more favourable in high-risk subset of patients and lesions, most of whom are 'off-label', than in low-risk situations [Marzocchi et al. 2007; Tu et al. 2007 ]. Certainly, more evidence is needed for each specific subgroup of patients.
Other drug-eluting stent systems
To date, SES and PES have the most extensive accumulated clinical experience and are the only FDA-approved DES. However, several other DES have been developed and are currently available for clinical use in Europe and other countries, and others are under early clinical or preclinical investigation. Safety profile of these DES may be significantly different from the SES and the PES, due to the stent design, different pharmacokinetics and pharmacodynamics of the drugs loaded on the stent, or to the properties of the polymers. Important progress could be achieved with bioabsorbable polymers, biodegradable stents, and nonpolymerbased devices.
The most studied 'second-generation' DES are the Endeavor™ zotarolimus-eluting stent (Medtronic Inc, Minneapolis, MN) [Fajadet et al. 2006] , and the XIENCE V™ everolimuseluting stent (Abbott Vascular, Abbott Park, IL). Both these stents showed significant reduction of restenosis and new revascularizations compared to BMS. In the ENDEAVOR trials, 3-year Kaplan-Meier estimates of thrombosis free survival per protocol were higher in patients treated with the active stent (99.7 versus 98.8% in the BMS stent; p = 0.020). Using the ARC definition of definite or probable stent thrombosis, there was a trend toward reduced rates of stent thrombosis with the Endeavor stent (0.5 versus 2.3% in patients treated with BMS; p = 0.067). These results were maintained when patients with late TLR were censored from the analysis [Kuntz, 2007] . Recently presented data from the ENDEAVOR 4 study showed the Endeavor stent to be noninferior to the PES in terms of the primary clinical end point, target vessel failure, a composite of TVR, death, or MI that could not be attributed to anything but the target vessel. However, the PES showed consistent and statistically significant superiority in all 8month secondary angiographic endpoints, and the incidence of 12-month stent thrombosis in the Endeavor arm was slightly higher than in the PES arm (6 patients vs 1, p = NS) (M. Leon, personal communication, TCT meeting, Washington D.C., October 2007). Preclinical studies with the everolimus-eluting stent showed improved endothelialization and limited chronic inflammation compared with other DES. At the 1-year follow-up of the multicenter randomized SPIRIT III trial, the everolimus-eluting stent demonstrated noninferior rates of target vessel failure compared with the PES, fewer revascularization procedures, and similar rates of death, MI, and stent thrombosis. However, longer follow-up and larger cohorts of patients are necessary for a reliable evaluation of the safety profile of these new devices.
Conclusions
Drug-eluting stents are associated with a significant and sustained reduction in the need for repeat coronary revascularization procedures compared with bare metal stents. However, DES may engender adverse arterial responses, including delayed endothelialization, impaired vascular healing, and hypersensitivity to the polymeric coating that altogether may predispose to ST. Albeit infrequent, stent thrombosis is often associated to catastrophic clinical consequences such as myocardial infarction or sudden cardiac death, and it therefore deserves the highest surveillance.
In clinical trials and post-marketing registries, the majority of the episodes of ST occurred within the first month after the procedure, and are probably attributable to procedural and favoured by clinical factors. Accordingly, early ST rates are similar between DES and BMS. Differently, during long-term follow-up from randomized controlled trials that compared sirolimus-and paclitaxel-eluting stent to BMS, there was no apparent difference in overall ST frequency, although there was a relative numeric excess of ST late after DES implant. It should be highlighted that many cases of DES thrombosis over long-term may also depend on procedural issues (e.g. incomplete stent deployment, insufficient overlapping, inappropriate technique for bifurcations), that are probably more associated with restenosis in BMS. However, no differences in the end points of death and myocardial infarction between DES and BMS were observed.
Thus, when used according to labelled indications, DES use appears safe. In large registries enrolling many complex (and off-label) patients and lesions, late DES thrombosis occurred more frequently, but the true magnitude of this risk is uncertain, as well as its time-window. Remarkably, also in this real-world scenario rates of death and myocardial infarction were similar or even lower in the DES group compared with the BMS after adjustment for baseline clinical, angiographic and procedural characteristics. Different regimens of dual antiplatelet therapy between BMS (1 month) and DES (progressive increase over time) may have contributed to improve the outcome in the DES groups. Additional research is needed to clarify the safety and effectiveness of DES use in specific off-label populations. The fact that very late stent thrombosis did not significantly impact late mortality or MI after DES placement may relate, in part, to the beneficial effect of DES on the prevention of death and MI due to restenosis and restenosis-related revascularization procedures. In fact, even if restenosis has historically been considered a benign process, in recent studies it was associated with a small but non-negligible incidence of death or nonfatal MI, either before or as a complication of the revascularization required to treat the restenotic lesion [Chen et al. 2006; Listro et al. 2006; Stone et al. 2007 ].
Currently available data are insufficient to support a specific duration of dual antiplatelet therapy for all patients [Airoldi et al. 2007 ]. Dual antiplatelet therapy is recommended in patients at low risk for bleeding for at least 1 year. Additional research is needed to define the ideal duration of dual antiplatelet therapy in specific populations.
Advances in stent platforms, polymer carriers and drugs are being evaluated to enhance long-term safety and to reduce the risk of late ST associated to DES.
